Treatment for relapsed/refractory illness must be determined based on prior therapy as well as The key reason why why the initial remedy was now not appropriate (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold conventional therapy for clients with relapsed/refractory disease, determined by the results of various stage I-III tri